NASDAQ: PHARPharming Group Nv Stock
$10.78+0.25 (+2.37%)
Updated Apr 15, 2024
PHAR Price
$10.78
Fair Value Price
$18.62
Market Cap
$723.42M
52 Week Low
$9.70
52 Week High
$16.71
P/E
-61.95x
P/B
3.04x
P/S
2.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$266.65M
Earnings
-$11.72M
Gross Margin
89.7%
Operating Margin
-4.9%
Profit Margin
-4.3%
Debt to Equity
1.12
Operating Cash Flow
-$19M
Beta
0.6
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
PHAR Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PHAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHAR ($10.78) is undervalued by 42.11% relative to our estimate of its Fair Value price of $18.62 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PHAR ($10.78) is significantly undervalued by 42.11% relative to our estimate of its Fair Value price of $18.62 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PHAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PHAR due diligence checks available for Premium users.
Be the first to know about important PHAR news, forecast changes, insider trades & much more!
PHAR News
Valuation
PHAR fair value
Fair Value of PHAR stock based on Discounted Cash Flow (DCF)
Price
$10.78
Fair Value
$18.62
Undervalued by
42.11%
PHAR ($10.78) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PHAR ($10.78) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PHAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PHAR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-61.95x
Industry
14.94x
Market
41.94x
PHAR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.04x
Industry
5.88x
PHAR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHAR's financial health
Profit margin
Revenue
$90.2M
Net Income
-$3.5M
Profit Margin
-3.8%
PHAR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PHAR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$514.3M
Liabilities
$271.2M
Debt to equity
1.12
PHAR's short-term assets ($343.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHAR's short-term assets ($343.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHAR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PHAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$12.9M
Investing
-$4.3M
Financing
-$1.1M
PHAR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHAR vs Biotech Stocks
Pharming Group Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.